The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020

Page created by Cody Simmons
CONTINUE READING
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
The Universal
 Flu Vaccine
 Multi-Season
 Multi-Strain
 Flu Vaccine
CORPORATE PRESENTATION
    AUGUST 2020
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
2

SAFE HARBOR STATEMENT
This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction.

All statements in this communication, other than those relating to historical facts, are "forward-looking statements" within the meaning of the United States
Private Litigation Reform Act of 1995. You can identify forward-looking statements by terms including ‘‘anticipates,’’ ‘‘believes,’’ ‘‘could,’’ ‘‘estimates,’’
‘‘expects,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘plans,’’ ‘‘potential,’’ ‘‘predicts,’’ ‘‘projects,’’ ‘‘should,’’ ‘‘will,’’ ‘‘would,’’ and similar expressions intended to identify forward-
looking statements. These forward-looking statements relate to our business and financial performance and condition, as well as our plans, strategies,
objectives and expectations for our business, operations and financial performance and condition. However, these forward-looking statements are not
guarantees of future performance and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially
from our expectations include, among others: the risk that drug development involves a lengthy and expensive process with uncertain outcome; BiondVax's
ability to successfully develop and commercialize its vaccine; the length, progress and results of any clinical trials; the introduction of competing products; the
impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to
commercialize BiondVax's products; the difficulty in evaluating business prospects; the adequacy of available cash resource and the ability to raise capital
when needed; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; changes in the global
pharmaceutical industry; changes in customers’ budgeting priorities; European Medicines Agency and other regulatory authority approvals; natural disasters;
labor disputes; rising interest rates; general market, political or economic conditions in the countries in which we operate; pension and health insurance
liabilities; volatility or crises In the financial market; arbitration, litigation and regulatory proceedings; and war or acts of terror.

Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You
should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking
statements will be achieved or will occur. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the
Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and
Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC. Readers are urged to
carefully review and consider the various disclosures made in the Company’s SEC reports, which are designed to advise interested parties of the risks and
factors that may affect its business, financial condition, results of operations and prospects. These forward-looking statements speak only as of the date of
this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new information,
future events or otherwise, except as required by law.

One • For All : The Universal Flu Vaccine
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
3

     BIONDVAX ON THE RADAR

More News: http://www.biondvax.com/press-releases/in-the-news/

    One • For All : The Universal Flu Vaccine
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
4

            A SEASONAL PROBLEM… A PANDEMIC THREAT
                                                   The Flu: A Serious Public Health Challenge

           SEASONAL FLU – DESPITE ANNUAL VACCINE PRODUCTION (500 MILLION DOSES1)

                                        Flu cases:
                                                                                          Severe illness:                                       Deaths:
                                       up to 20%2
                                                                                          3 – 5 million3                                        650,0003
                                      or 1.5 billion
           ❖ At-risk Seniors: 89% of deaths & most hospitalizations4
           ❖ High economic burden: Over $361B in the USA4
           ❖ USA: Up to 80,000 deaths and 900,000 hospitalizations5

           PANDEMIC FLU
           ❖ New pandemic strain: When?… Where?... Which?
           ❖ Higher morbidity & mortality worldwide
           ❖ Estimated cost in US $413B to $3.79T4
1 WHO: http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/ and https://en.wikipedia.org/wiki/Influenza_vaccine#Uptake; 2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596521/;
3 WHO: http://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year (varies annually); 4 White House Council of Economic Advisors
(CEA), Mitigating the Impact of Pandemic Influenza through Vaccine Innovation, September 2019.; 5CDC: www.cdc.gov/flu/about/disease/burden.htm and https://www.nytimes.com/2018/10/01/health/flu-
deaths-vaccine.html
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
5

       CURRENT VACCINE FALLS SHORT: THE MISMATCH
                                The Flu Virus: Frequent and Unpredictable Mutations
                                                                                              Seasonal Flu Vaccine Effectiveness1
                                                                                              Average 40%, Elderly as low as 9%2
                                                                                             2004-05        10%
                                                                                             2005-06                21%
                                                                                             2006-07                                     52%
                                                                                             2007-08                            37%
                                                                                             2008-09                              41%
                                                                                             2009-10                                          56%
                                                                                             2010-11                                            60%
                                                                                             2011-12                                   47%
       Why current solutions fall short…                                                     2012-13                                    49%
                                                                                             2013-14                                      52%
       • Past strains selection → Mismatch phenomenon                                        2014-15              19%                                   100%
                                                                                             2015-16                                    48%           Protection
       • Previous season’s vaccine will not necessarily                                      2016-17                             40%
           protect against next season’s flu strains                                         2017-18                            38%
                                                                                             2018-19                      29%
       • 4-6 month production lag                                                                             Measles, Rubella, Diphtheria, Tetanus, etc. 95%-99%

1   VE data: CDC, including https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm [Retrieved 29 October 2019]
2   World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
6

       THE ELDERLY – AT RISK AND IN NEED
                                                                              •    ~80% of seasonal flu related death occurs in elderly1
                                                                              •    Seasonal vaccine effectiveness as low as 9% for elderly2
                                                                              •    80% of older adults have at least one chronic condition3
                                                                              •    Influenza worsens outcomes of chronic illness
                                                                              •    Elderly flu cost in US estimated4 at $56B per year
                                                                                   (hospitalization, mortality, lost earnings)

    NIH: “During the period from 1989 to 1997 the vaccination rate for
    elderly persons ≥65 years of age in the US increased from 30 to 67%.
    Despite this increase in coverage, mortality and hospitalization rates
    continued to increase rather than decline as would be expected...”
                                                                           International Journal of Epidemiology5 (Vol. 35, Issue 2, P352-353)

1 Vaccine journal: www.sciencedirect.com/science/article/pii/S0264410X15002315, Table 3; 2 WHO:
http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf
3 https://www.ncoa.org/healthy-aging/chronic-disease/; 4 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25

(2007) 5086–5096; 5 https://academic.oup.com/ije/article/35/2/352/694736;
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
7

        MEETING MILESTONES & CATALYSTS
                               Solid Science, Phase 3 Clinical Stage, Strong IP

                                                                                               -   Ongoing Pivotal Clinical
  Technology developed                                                                             Efficacy Phase 3 trial
   by Prof. Ruth Arnon     TASE June 2007              Nasdaq: BVXV          Commercial
   Head BiondVax’s SAB      Delisted 2018                  2015              pilot facility        (Europe)

                    2005

  Mid 90’s                                                                                    2020
                  BiondVax                      7 Successful Clinical Trials
                 operational          •   Two Phase 1/2 & Five Phase 2
                                      •   Israel, Europe, USA (NIH)                    .
                                      •   FDA IND / EMA SA
Co-Inventor of                        •   818 young adult to elderly participants
                                      •   M-001 shown to be safe and
                                          immunogenic in all studies

       One • For All : The Universal Flu Vaccine
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
8

                M-001: A COMMON DENOMINATOR OF FLU VIRUSES
                                                                Target Common Regions: Nine common flu regions (epitopes)
                                                                connected to make one recombinant protein (M-001) produced in E.coli

                                                                             BiondVax’s M-001 Key Advantages              Existing vaccines

                                                                             Universal: Broad coverage types A&B          Strain specific

                                                                             Single formulation enabling                  New vaccine every
                                           HemAgglutinin (HA)

                                                                             year-round vaccination                       year
                      NucleoProtein (NP)
Matrix protein (M1)

                                                                             Quick, robust year-round production          Long (4-6 month)
                                                                             through E.coli fermentation (6-8 weeks)      production cycle

                                                                             Induces cellular (CMI) and enhances
                                                                                                                          Limited vaccine
                                                                             humoral (HAI priming effect) immune
                                                                                                                          effectiveness
                                                                             response to flu

                                                                             Shelf life up to 24 months at 2-8⁰C          Not applicable, since
                                                                             (testing is ongoing) and 6 months at ~25⁰C   new vaccine every
     Now in prefilled syringes                                               (room temperature)                           season

         One • For All : The Universal Flu Vaccine
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
9

  M-001: THE UNIVERSAL FLU VACCINE
M-001’s dual mode of action potentially offers multi-season and multi-strain protection
• Flu viruses are intracellular parasites
• Most of their lifecycle occurs inside our cells, thus are out of the reach of antibodies
• Our immune system mainly fights viral infection with cellular immunity via cytokines
                                    Our immune system has 2 arms:
          Cellular (CMI)                                                     Humoral (HAI)
     Works inside infected cells           BiondVax’s M-001                 Works outside cells
                                          Dual Mode of Action
              T-cell           Directly                         T-cell         B-cell
                               induces                          priming
     e.g. T-Helper, CD4, CD8   T-Cells                          effect          Produce
        Produce anti-viral                                      enhances       Antibodies
        cytokines such as                                       B-Cell
                                                                responses
       IL-2           IFN-g

                                                                     Current vaccines mainly induce
                                                                    only flu strain-specific antibodies

 One • For All : The Universal Flu Vaccine
The Universal Flu Vaccine - Multi-Season Multi-Strain Flu Vaccine AUGUST 2020
10

    ADVANCED CLINICAL DEVELOPMENT
                    M-001: Safe and Immunogenic in Young Adults to Elderly
   •    No treatment-related severe adverse events                            Group        Day 0    Day 21               Day 42
   •    Adverse events were mild to moderate                                 Treatment     M-001     M-001      Seasonal or Pandemic HA
   •    All adverse events observed were transient                            Control      Saline    Saline     vaccine to all participants

   •    Immunity: Cellular induced, humoral enhanced                        Baseline                  CMI                            HAI

                                                                               Total
 Phase          Trial          Year             Population (age)                                              Results
                                                                            Participants
  1/2       BVX-002            2009          Younger Adults (18-49)               63
  1/2       BVX-003            2010           Older Adults (55-75)                60
                                                                                              M-001 was well tolerated and a cellular
   2        BVX-004            2011          Younger Adults (18-49)              200           (CMI) and humoral (priming effect)
   2        BVX-005            2012                Elderly (65+)                 120             immune response was observed
   2        BVX-006            2015           Older Adults (50-65)                36
   2b       BVX-007a         2015-16            EU Adults (18-60)                219
   2        BVX-008b           2018            USA Adults (18-49)                120            Safe and significant T cell responses
                                                                                 818

   3        BVX-010            2018         E. European Adults (50+)           12,463          Results expected by end of Oct. 2020
a BVX-007 was conducted in collaboration with the EU’s UNISEC consortium.
  One • For All : The Universal Flu Vaccine
b BVX-008 conducted and led by NIAID/NIH. Clinical study report submitted June 2020.
11

            M-001: INDUCES CELL MEDIATED IMMUNITY (CMI)
Direct Evidence: CD8, CD4 T-cell Activated Cells Produce TH1 Cytokines (IFN-gamma, IL-2 & TNF-alpha)
                                                 BVX0051: CD4 & IFN-gamma in Elderly                                                                                                BVX0051: CD8 & IFN-gamma in Elderly
                                                0.3                                                                                                                                   0.3               *                                   M-001 twice Day 0              *
                                                                                          M-001 twice Day 0

                                                                                                                                                     % positive cells (Mean + SE)
                % positive cells (Mean + SE)

                                               0.25
                                                                                                                                 **                                                 0.25
                                                                                                                                                                                                                                            M-001 twice Day 42
                                                               *               *          M-001 twice Day 42
                                                0.2                                                                                                                                   0.2

                                               0.15                                             *               *                                                                   0.15

                                                0.1                                                                                                                                   0.1

                                               0.05                                                                                                                                 0.05                                                                                           * P
12

                           M-001: ENHANCES HUMORAL IMMUNITY (HAI)
   Indirect Evidence: Extending T-Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines
   BVX0051: 2011/12, age 65+ YO
                           70
                                          *
                                                                                                   “M-001 can provide broadened enhanced immunity
                           60                                    TIV    Twice M-001 + TIV          extending even to influenza strains destined to
        % Seroconversion

                           50
                           40
                                                                                                   circulate in future years.” – Vaccine 2
                           30
                           20
                                                                                                                                                                      70
                           10                                                                      In 2011 we                                                                                     *
                            0                                                                      administered M-001                                                 60

                                                                                                                                             % Seroprotection (HAI)
                                A/California/7/09   A/Perth/16/09       B/Brisbane/60/08
                           H1N1 pandemic swine flu                                                 to seniors 65+                                                     50

   BVX003: 2009, age 55-75 YO
                                                                                                   (BVX005)
                                                                                                                                                                      40
                           80                              TIV         Twice M-001 + TIV
                           70
                                                                                                   4 years later, 5 times                                             30
                                                                                                   more seniors were
        % seroconversion

                           60
                                                                                                                                                                      20
                           50                                                                      seroprotected from a
                           40                                                                      new epidemic strain                                                10
                           30
                                                                                                   (A/Swiss) that didn’t                                               0
                           20
                           10                                                                      exist in 2011!                                                          TIV 2011/12   M-001 & TIV 2011/12

                            0
                                A/Brisbane/59/07    A/Brisbane/10/07     B/Brisbane/60/08                                                                                                        * P
13

  PIVOTAL CLINICAL EFFICACY PHASE 3 TRIAL (EUROPE)
    A pivotal, multicenter, randomized, modified double-blind, placebo-controlled phase 3 trial to
 assess the safety and clinical efficacy of M-001, an influenza vaccine, administered intramuscularly
                        twice in older adults and the elderly (≥50 years of age)

Trial Design:             Cohort 1 (4,042 enrolled & randomized Aug-Oct 2018)             Professor Shai Ashkenazi, MD
Flexible                  Cohort 2 (8,421 enrolled & randomized July-Nov 2019)
enrollment
                Day 1          Day 21        Day 202               ~12,400 participants

Experimental    1mg M-001      1mg M-001                            Age 50+ (half 65+)
                                             Safety, RT-PCR or       Two flu seasons
                                             culture on any ILI
Control         Placebo        Placebo       (during flu season)    Results by end of
                                                                      October 2020        BiondVax’s Medical Director

                                                                                          • Dean of Medicine, Ariel University
                                                                                          • Former Director of Pediatrics at
 • ILI symptoms active surveillance throughout both flu seasons                             Schneider Children’s Medical
                                                                                            Center of Israel
 • Primary endpoints: Safety & clinical efficacy by reduction of illness rate             • Former Lea and Arieh Pickel Chair
                                                                                            for Pediatric Research, Sackler
 • Secondary endpoint: Reduced severity of influenza illness                                Faculty of Medicine
                                                                                          • Experienced clinician-researcher;
                                                                                            guided vaccines through clinical
                                                                                            and regulatory approval to market

   One • For All : The Universal Flu Vaccine
14

BIONDVAX’S NEW MANUFACTURING FACILITY
              From Lab to Pilot Mid-Size Commercial Scale Facility
• Funding: EIB, BiondVax, and Israel’s Ministry of Economy & Industry
• Target annual capacity: Up to between 10 and 20 million doses in bulk
• Goal: Year-round GMP production & stockpile per market demand

                                                         Jerusalem BioPark
                                                         Hadassah Ein Kerem Campus
                                                         Jerusalem, Israel

One • For All : The Universal Flu Vaccine
15

           BIONDVAX: FIRST-IN-CLASS, BEST-IN-CLASS
                                                                                                    Phase
       Player                                  Technology                                  Pre-                                               Status
                                                                                                     I      II   III
                                                                                         clinical
BiondVax                                                                                                               Statistically significant European Ph2b trial UNISEC
                            M-001: Synthetic protein B- & T-cell peptides (HA, M1,
                                                                                                                       consortium. NIAID/NIH sponsored ongoing collaboration
                            NP). Broad coverage, 6 completed clinical trials in adults        N=13,281                 Phase 2 in USA.
                            18 to 65+
                                                                                                                       Ongoing pivotal, clinical efficacy Phase 3 trial (Europe).

Imutex +                                                                                                               2016: Seek created Imutex with hVIVO
                            FLU-V: 4 T-cell peptides adjuvanted formulation
                            Challenge and immunogenicity trials                          N=408                         2020: hVIVO acquired by Open Orphan (AIM: ORPH)
                                                                                                                       Phase 2 trials (field, challenge) positive results
                            M2SR (RedeeFlu): Single replication virus; Broadening                                      Phase 2 challenge, intranasal, 2019 interim results
                            immunogenicity to flu sub type H3N2.                                                       ‘serum antibody response.’ Equity funding $27m,
                            First in human results reported 2018. Immunogenic in         N=389                         including $5.5m Aug 2017; $27m gov’t grants.
                            mice                                                                                       NIAID sponsored Phase 1, began 2019.
                                                                                                                       2019: Phase 1 CD8 T Cell response. Phase 2a results
                            OXV836: Recombinant poly-Arg NP (H1 strain) in VLP,                                        expected 2021. Raised total €14.3m + up to €32.6m
                            produced in E.coli. CD8 T-cell activation
                                                                                         N=372                         grants and equity (also towards corona vaccine
                                                                                                                       candidate, 2020).
                                                                                                                       Phase 1 interim results (2019), elicited cross reactive
                            Chimeric H1 targeting stalk of group 1 (H1,H2,H5)            N=108                         anti-stalk serum IgG antibodies. NIAID-sponsored Phase
                                                                                                                       1 in children.

                            H1ssF_3928: H1 HA stem + ferritin nanoparticle.
                            NIH infrastructure                                           N=70                          Phase 1 began 2019, results expected 2020.

            Academic labs
                            Stem-only immunogens based on rational design; DNA
                            and RNA vaccines. Heterosubtypic protection in mice,                                       Results in animals.
                            ferrets, primates

         One • For All : The Universal Flu Vaccine
Based on publicly available information. Last updated February - July 2020
16

     SUMMARY FINANCIAL DATA
     •   Lean structure with 25 employees. Manufacturing scale-up
         and operating burn ~$700K/month
     •   Fully funded through end of ongoing Phase 3 clinical trial:
           •   €24M EIB non-dilutive co-funding agreement1
           •   Rights offering July 2019, $20M gross proceeds2
                                                                                         American Depository Shares ticker:

           •   Secondary offering Sept 2017, $10M gross proceeds
           •   Government of Israel support from Ministry of
               Economy and Industry’s Israel Investment Center, and
                                                                                                 BVXV
               royalty-based grants from the Israel Innovation
               Authority (formerly Office of the Chief Scientist)

1 European Investment Bank (EIB) €24M support for M-001 Phase 3 trials and commercial production also includes:
   • Milestone based drawdowns received in 2018 and 2019
   • Zero-percent fixed interest loan for five years after each of the 4 drawdowns
   • Variable remuneration based on royalties of net sales
2 http://www.biondvax.com/2019/07/biondvax-announces-rights-offering-fully-subscribed-at-us20-million/
17

             FLU VACCINES – A LARGE AND GROWING MARKET
        The Big Four Flu Vaccine 2019 Revenue                                                                                      Flu Vaccine Market
                                                                                                         Seasonal Flu
                                                                                                            o Worldwide: Up to $5.2B global market in 2018;
                                              $0.69B6                                                         expected to grow to $7.5B by 20241
                                                                                                            o USA: $2.6B in 20192; ~174M doses in 2019/2010
                                              GSK
                                              17%                                                           o Forecasted CAGR of 6.37%1
            $0.11B9         3%

                                                                                                         Pandemic Flu
                                                                             Sanofi                        o Swine Flu (A/H1N1) 2009 + first half of 2010 sales: $5-6B
                               Seqirus                                        51%
                                29%
                                                                                                             worldwide by Novartis, GSK and Sanofi (on top of
                                                                                                             seasonal flu vaccine sales)4
                                                                                                           o >1B pandemic vaccines doses ordered in 200911

          $1.20B8                                                                                           “The United States has spent approximately $1 billion in these
       2014/5: CSL bought                                                                                   [H5N1 flu vaccine stockpile] efforts to date.”5
       Novartis’ Flu vaccine unit,
       rebranded to Seqirus                                                 $2.12B7                         “…part of our nation’s overall pandemic preparedness
                                                                                                            strategy…stockpile of bulk vaccine…for influenza viruses with
                                                                    2017: Acquired Protein
                                                                    Sciences for $750M                      pandemic potential to vaccinate 26 million people immediately
                                                                                                            after a pandemic is declared.”12

(1) https://www.researchandmarkets.com/research/5q8dvw/ (2) https://www.coherentmarketinsights.com/market-insight/us-influenza-vaccines-market-1127 (3) https://www.marketwatch.com/press-
release/united-states-influenza-vaccine-market-size-global-industry-analysis-segments-top-key-players-drivers-and-trends-to-2022-2019-02-27 (4) www.vaczine-analytics.com/ER_January_100128s.pdf (5)
http://www.who.int/immunization/sage/meetings/2013/november/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf (6) https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-
2019#tab-1-4 [At exchange rate 1.28] (7) https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-30-00 [At exchange rate 1.12] (8) YE June 2019 https://medialib.csl.com/-
/media/shared/documents/results/2019-fy-analyst.pdf (9) https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2018/PDF/AstraZeneca_AR_2018.pdf, page 69. Likely less than $0.11B
in 2019, was not detailed in AZ FY19 annual report (10) https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm (11) https://www.theglobeandmail.com/life/health-and-fitness/health/conditions/how-
vaccines-became-big-business/article572731/ (12) https://www.phe.gov/ASPRBlog/Lists/Posts/Post.aspx?ID=322
18

    MANAGEMENT

                                         Tamar
   Ron Babecoff                                                        Uri Ben-Or                         Elad Mark                    Joshua Phillipson
         DVM, MEI                      Ben-Yedidia                         CPA, MBA                  BSc Engineering, MBA                   Hon. BSc, MBA
                                               PhD

       Founder,                     CSO & Clinical Trial                                                                               Director of Business
                                                                              CFO                              COO
    President & CEO                      Leader                                                                                         Development & IR
• DVM (University of Liège)       • Co-inventor of the universal   • BA Business (College of       • BSc. Engineering (Afeka Tel       • Hon. BSc. (University of
• Master in Entrepreneurship &      flu vaccine                      Administration)                 Aviv College of Engineering)        Toronto)
  Innovation (ISEMI, Swinburne)   • PhD (Weizmann Institute of     • MBA (Bar Ilan University)     • MBA (Open University of Israel)   • MBA (Ben Gurion University
• Omrix Biopharmaceuticals Ltd      Science)                                                       • Principal bioprocess engineer       of the Negev)
                                                                   • Certified Public Accountant
  (Marketing Manager)             • Biotechnology General Ltd.       (CPA)                         • Novartis (Technical Project       • Accenture (Business
• Dexcel Pharma (Regional                                          • Glycominds Ltd. (VP             Manager - Process)                  Management Consultant)
  Export Manager)                                                    Finance)                                                          • BioData Ltd. (Marketing
                                                                   • Menorah Capital Markets                                             Manager)
                                                                     (Comptroller)

  One • For All : The Universal Flu Vaccine
19

 BOARD OF DIRECTORS
Mr. Mark Germain             Aentib Group (Managing Director), Pluristem (Director). Founder, director, chairman,
Chairman of the Board        and/or investor in over twenty biotech companies
Ron Babecoff, DVM, MEI       Omrix Pharmaceuticals Ltd (Marketing Manager), Dexcel Pharma Technologies Ltd.
Founder, President and CEO   (Formerly Dexxon, Regional Export Manager)
Mr. Isaac Devash, MBA        Credit Suisse First Boston (Investment Banking), Private equity and venture capital funds
Director                     (Founder)
Dr. Morris C. Laster, MD     BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital Spark (CEO),
Director                     Kitov Pharmaceuticals (Co-founder, Director)
Dr. George Lowell, MD
                             ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital (Consultant)
Director
Dr. Yael Margolin, PhD
                             Gamida Cell Ltd. (Nasdaq: GMDA) (President, CEO, Director), Denali Ventures LLC (VP)
External Director
Mr. Samuel Moed
                             Bristol Myers Squibb (NYSE: BMY) (Senior Vice President, Corporate Strategy)
Director
Mr. Adi Raviv, MBA
                             Capacity Funding LLC (Principal)
External Director
Prof. Avner Rotman, PhD      Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman, Steering
Director                     committee)
Dr. Ruth Ben Yakar, PhD
                             BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect Biotechnology (Director)
Director

One • For All : The Universal Flu Vaccine
20

CAP TABLE
      Nasdaq: BVXV             ADS                                     ADS           Expiration
                                                       %
      July 15, 2020         Outstanding                                Price           Date

  Ordinary ADS                 11,520,566              95%

  Options + RSUs                599,902                5%              Variable          Variable

  Fully Diluted Shares
                               12,120,468           100.00%
  Outstanding

  •    Voluntarily delisted from Tel Aviv Stock Exchange January 22, 2018. (ADS-Shares 1:40 ratio)
  •    Warrants issued to investors in connection with BiondVax’s IPO on Nasdaq in 2015 and traded
       under symbol BVXVW expired in May 2020.

One • For All : The Universal Flu Vaccine
21

           IP: COMPREHENSIVE AND EXPANDING COVERAGE
     • 74 Patents & 11 Pending Applications
     • Covering polypeptides, polynucleotides, compositions, uses, formulations, production
     • Expiration to 2035
Title                                 International                                    Priority &
                                                            Subject Matter                                       Status                                    Expiry
(updated: March 2020)                 Publication                                      Assignee
                                                             Vaccine comprising        11/30/1998: Yeda          Granted: USA
Peptide-Based Vaccine for
                                       WO 00/032228          different epitopes of     R&D licensed to           Expired: 1, 3, 5, 12, 13, 15, 19, 20,     USA: Aug 2020
Influenza
                                                             the virus                 BiondVax                  22, 24, 25, 26, 31, 33, 35, 36

                                                             Wide–range vaccines
                                                                                       12/6/2005: Yeda R&D       Granted: 1, 2, 3, 5, 9, 12, 13, 14, 18,   Dec 2026
Improved Influenza Vaccine             WO 2007/066334        – broad strain and
                                                             extended protection       licensed to BiondVax      19, 20, 23, 25, 28, 31, 32, 33, 35, 36    USA: Jan 2027

                                                             Vaccines comprising                                 Granted: 1, 2, 3, 4, 5, 6, 7, 8, 9, 11,
                                                                                                                                                           Aug 2028
Multimeric Multi-Epitope Influenza                           multiple copies of                                  12, 13, 15, 16, 17, 18, 19, 20, 21, 22,
                                       WO 2009/016639                                  8/2/2007: BiondVax                                                  Brazil: Nov 2029
Vaccines                                                     several epitopes –                                  23, 24, 25, 27, 28, 29, 30, 31, 32, 33,
                                                             current product                                                                               USA: Aug 2031
                                                                                                                 34, 35, 36
Multimeric Multi-Epitope                                     Use of Multimeric as
                                                                                                                                                           Feb 2031
Polypeptides in improved Seasonal      WO 2012/114323        a primer to               BiondVax                  Granted: 1, 5, 36
and Pandemic Influenza Vaccines                              conventional vaccines                                                                         USA: May 2031

Vaccine Compositions of
                                                             Production &                                        Allowed: 1, 21, 36
Multimeric Multi-epitope Influenza     WO 2015/151103                                  4/3/2014: BiondVax                                                  April 2035
                                                             formulation                                         Pending: 5, 6, 10, 15, 17, 19
Polypeptides and their Production

1=Australia, 2=Austria, 3=Belgium, 4=Brazil, 5=Canada, 6=China, 7=Croatia, 8=Czech Republic, 9=Denmark, 10=Europe,
11=Finland, 12=France, 13=Germany, 14=Greece, 15=Hong Kong, 16=Hungary, 17=India, 18=Ireland, 19=Israel, 20=Italy,
21=Japan, 22=Korea, 23=Luxembourg, 24=Mexico, 25=Netherlands, 26=New Zealand, 27=Poland, 28=Portugal, 29=Romania,
30=Russia, 31=Spain, 32=Sweden, 33=Switzerland, 34=Turkey, 35=UK, 36=USA.
The Universal
 Flu Vaccine
 Multi-Season
 Multi-Strain
 Flu Vaccine
CONTACT INFORMATION:
JOSHUA PHILLIPSON
j.phillipson@biondvax.com
+972-8-930-2529
www.biondvax.com
You can also read